{
    "htmlLang": "zh-Hant",
    "docTitle": "新聞發佈 - PharmaEngine",
    "hero": {
        "title": "新聞發佈",
        "image": "/images/business-man-1031755-1242.jpg 1242w,/images/business-man-1031755-1536.jpg 1536w,/images/business-man-1031755-1920.jpg 1920w"
    },
    "news": {
        "subject": {
            "title": "新聞摘要"
        },
        "tabs": [
            {
                "id": "2020",
                "label": "2020",
                "content": [
                    {
                        "href": "/newsView",
                        "date": "2020/07/02",
                        "brief": "智擎合作夥伴Ipsen於世界腸胃道癌症大會發表安能得®合併療法 作為第一線轉移性胰臟癌治療之第一/二期臨床試驗數據",
                        "image": "/images/4M1A5875-100.jpg 100w,/images/4M1A5875-200.jpg 200w,/images/4M1A5875-400.jpg 400w"
                    },
                    {
                        "href": "/newsView",
                        "date": "2020/06/01",
                        "brief": "智擎合作夥伴NANOBIOTIX於ASCO 2020年會上公布PEP503（NBTXR3, HENSIFY）頭頸部癌症第一期臨床試驗擴展階段的正向數據",
                        "image": "/images/4M1A5875-100.jpg 100w,/images/4M1A5875-200.jpg 200w,/images/4M1A5875-400.jpg 400w"
                    },
                    {
                        "href": "/newsView",
                        "date": "2020/02/11",
                        "brief": "智擎宣布合作夥伴NANOBIOTIX取得PEP503（NBTXR3, HENSIFY）獲得美國FDA新藥快速審查資格",
                        "image": "/images/4M1A5875-100.jpg 100w,/images/4M1A5875-200.jpg 200w,/images/4M1A5875-400.jpg 400w"
                    }
                ]
            },
            {
                "id": "2019",
                "label": "2019",
                "content": [
                    {
                        "href": "/newsView",
                        "date": "2019/09/10",
                        "brief": "智擎合作夥伴IPSEN與SERVIER於世界肺癌大會發表安能得於二線小細胞肺癌之第二/三期臨床試驗第一階段初步正向數據，並宣布進入第二階段病患收案",
                        "image": "/images/4M1A5875-100.jpg 100w,/images/4M1A5875-200.jpg 200w,/images/4M1A5875-400.jpg 400w"
                    },
                    {
                        "href": "/newsView",
                        "date": "2019/06/04",
                        "brief": "智擎產品安能得及HENSIFY臨床試驗於ASCO年會告捷",
                        "image": "/images/4M1A5875-100.jpg 100w,/images/4M1A5875-200.jpg 200w,/images/4M1A5875-400.jpg 400w"
                    },
                    {
                        "href": "/newsView",
                        "date": "2019/04/07",
                        "brief": "智擎宣布合作夥伴NANOBIOTIX取得PEP503（NBTXR3, HENSIFY）的歐盟上市許可",
                        "image": "/images/4M1A5875-100.jpg 100w,/images/4M1A5875-200.jpg 200w,/images/4M1A5875-400.jpg 400w"
                    },
                    {
                        "href": "/newsView",
                        "date": "2019/04/07",
                        "brief": "智擎宣布合作夥伴NANOBIOTIX取得PEP503（NBTXR3, HENSIFY）的歐盟上市許可",
                        "image": "/images/4M1A5875-100.jpg 100w,/images/4M1A5875-200.jpg 200w,/images/4M1A5875-400.jpg 400w"
                    }
                ]
            },
            {
                "id": "2018",
                "label": "2018",
                "content": [
                    {
                        "href": "/newsView",
                        "date": "2018/10/19",
                        "brief": "智擎合作夥伴NANOBIOTIX獲選於歐洲腫瘤醫學會（ESMO）及美國放射腫瘤學會年會（ASTRO）口頭發表PEP503（NBTXR3）於軟組織肉瘤之全球第二/三期臨床試驗正向數據詳細結果",
                        "image": "/images/4M1A5875-100.jpg 100w,/images/4M1A5875-200.jpg 200w,/images/4M1A5875-400.jpg 400w"
                    },
                    {
                        "href": "/newsView",
                        "date": "2018/07/11",
                        "brief": "智擎公司新藥安能得（ONIVYDE）獲台灣健保給付",
                        "image": "/images/4M1A5875-100.jpg 100w,/images/4M1A5875-200.jpg 200w,/images/4M1A5875-400.jpg 400w"
                    },
                    {
                        "href": "/newsView",
                        "date": "2018/06/18",
                        "brief": "智擎公司胰腺癌新藥安能得已於歐洲第三個主要國家上市銷售",
                        "image": "/images/4M1A5875-100.jpg 100w,/images/4M1A5875-200.jpg 200w,/images/4M1A5875-400.jpg 400w"
                    },
                    {
                        "href": "/newsView",
                        "date": "2018/05/02",
                        "brief": "智擎公司新藥安能得獲得新加坡藥證核准通過治療晚期胰臟癌",
                        "image": "/images/4M1A5875-100.jpg 100w,/images/4M1A5875-200.jpg 200w,/images/4M1A5875-400.jpg 400w"
                    },
                    {
                        "href": "/newsView",
                        "date": "2018/05/02",
                        "brief": "智擎公司新藥安能得獲得新加坡藥證核准通過治療晚期胰臟癌",
                        "image": "/images/4M1A5875-100.jpg 100w,/images/4M1A5875-200.jpg 200w,/images/4M1A5875-400.jpg 400w"
                    }
                ]
            }
        ]
    }
}
